查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1417486

下一代癌症诊断市场报告：2030 年趋势、预测和竞争分析

Next Generation Cancer Diagnostics Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

下一代癌症诊断的趋势和预测

到2030年，全球下一代癌症诊断市场预计将达到179亿美元，2024年至2030年的复合年增长率为11.0%。该市场的主要驱动力是癌症疾病的盛行率不断上升、对有效预后预测和早期检测各种类型癌症的需求以及对有效诊断的需求不断增长。主要相关人员越来越多地致力于创造新方法来全球下一代癌症诊断市场的未来前景广阔，生物标记开发、CTC分析、蛋白质体分析、磊晶分析和遗传分析市场都有机会。

下一代癌症诊断市场洞察

Lucintel 预计，在预测期内，治疗监测仍将是最大的部分，因为癌症治疗中免疫疗法和标靶治疗的普及增加了对有效治疗监测的需求。

由于拥有强大的医疗保健系统和对癌症研究的高度重视，北美在预测期内可能仍然是最大的地区。

常问问题

Q1.市场规模有多大？

A1. 到 2030 年，全球下一代癌症诊断市场预计将达到 179 亿美元。

Q2.市场成长预测如何？

A2. 下一代癌症诊断市场预计2024年至2030年复合年增长率为11.0%。

Q3.影响市场成长的主要驱动因素有哪些？

A3. 该市场的主要驱动因素是癌症疾病盛行率的不断上升、对各种类型癌症的有效预后预测和早期检测的需求以及对有效诊断的需求不断增长。主要相关人员越来越多地努力创建解决问题的新方法

Q4.市场的主要细分市场是什么？

A4. 由于生物标记开发、CTC分析、蛋白质体分析、表观磊晶分析和遗传分析市场的机会，全球下一代癌症诊断市场的未来充满希望。

Q5. 市场上主要企业有哪些？

A5. 下一代癌症诊断的主要企业如下。

  • Janssen Pharmaceuticals
  • Illumina
  • Novartis
  • F. Hoffmann-La Roche
  • Koninklijke Philips
  • QIAGEN
  • Agilent Technologies
  • Abbott
  • Thermo Fisher Scientific
  • GE HealthCare

Q6.未来最大的细分市场是什么？

A6.Lucintel 预计，在预测期内，治疗监测仍将是其最大的部分，因为癌症治疗中免疫疗法和标靶治疗的普及增加了对有效治疗监测的需求。

Q7. 未来五年预计哪个地区将成为最大的市场？

A7. 由于其强大的医疗保健系统和对癌症研究的高度重视，预计北美在预测期内仍将是最大的地区。

Q8. 可以客製化报告吗？

A8. 是的，Lucintel 提供 10% 的客製化服务，无需额外付费。

目录

第一章执行摘要

第二章全球下一代癌症诊断市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球下一代癌症诊断市场趋势（2018-2023）与预测（2024-2030）
  • 按癌症类型分類的全球下一代癌症诊断市场
    • 肺癌
    • 乳癌
    • 大肠直肠癌
    • 子宫颈癌
    • 其他的
  • 按技术分類的全球下一代癌症诊断市场
    • 下一代定序
    • 定量 PCR 和多重检测
    • 实验室晶片和逆转录 PCR
    • 蛋白质微阵列
    • DNA微阵列
  • 按功能分類的全球下一代癌症诊断市场
    • 治疗监测
    • 伴同性诊断
    • 预后
    • 癌症筛检
    • 风险分析
  • 全球下一代癌症诊断市场（按应用）
    • 生物标誌物开发
    • CTC分析
    • 蛋白质体分析
    • 磊晶分析
    • 遗传分析
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 按地区分類的全球下一代癌症诊断市场
  • 北美下一代癌症诊断市场
  • 欧洲下一代癌症诊断市场
  • 亚太地区下一代癌症诊断市场
  • 其他地区的下一代癌症诊断市场

第五章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 按癌症类型分類的全球下一代癌症诊断市场成长机会
    • 全球下一代癌症诊断市场的技术成长机会
    • 按功能分類的全球下一代癌症诊断市场成长机会
    • 全球下一代癌症诊断市场成长机会（按应用）
    • 全球下一代癌症诊断市场成长机会（按地区）
  • 全球下一代癌症诊断市场新趋势
  • 战略分析
    • 新产品开发
    • 扩大全球下一代癌症诊断市场的能力
    • 全球下一代癌症诊断市场的合併、收购和合资企业
    • 认证和许可

第七章主要企业概况

  • Janssen Pharmaceuticals
  • Illumina
  • Novartis
  • F. Hoffmann-La Roche
  • Koninklijke Philips
  • QIAGEN
  • Agilent Technologies
  • Abbott
  • Thermo Fisher Scientific
  • GE HealthCare
简介目录

Next Generation Cancer Diagnostics Trends and Forecast

The future of the global next generation cancer diagnostics market looks promising with opportunities in the biomarker development, CTC analysis, proteomic analysis, epigenetic analysis, and genetic analysis markets. The global next generation cancer diagnostics market is expected to reach an estimated $17.9 billion by 2030 with a CAGR of 11.0% from 2024 to 2030. The major drivers for this market are increasing prevalence of oncology disorders, requirement for effective prognosis and early detection of different types of cancer, as well as, growing efforts by important stakeholders to create novel approaches to address the growing need for effective diagnostics.

A more than 150-page report is developed to help in your business decisions.

Next Generation Cancer Diagnostics by Segment

The study includes a forecast for the global next generation cancer diagnostics by cancer type, technology, function, application, and region.

Next Generation Cancer Diagnostics Market by Cancer Type [Shipment Analysis by Value from 2018 to 2030]:

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Others

Next Generation Cancer Diagnostics Market by Technology [Shipment Analysis by Value from 2018 to 2030]:

  • Next-Generation Sequencing
  • qPCR & Multiplexing
  • Lab-On-A-Chip & Reverse Transcriptase-PCR
  • Protein Microarrays
  • DNA Microarrays

Next Generation Cancer Diagnostics Market by Function [Shipment Analysis by Value from 2018 to 2030]:

  • Therapeutic Monitoring
  • Companion Diagnostics
  • Prognostics
  • Cancer Screening
  • Risk Analysis

Next Generation Cancer Diagnostics Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Biomarker Development
  • CTC Analysis
  • Proteomic Analysis
  • Epigenetic Analysis
  • Genetic Analysis
  • Others

Next Generation Cancer Diagnostics Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Next Generation Cancer Diagnostics Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies next generation cancer diagnostics companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the next generation cancer diagnostics companies profiled in this report include-

  • Janssen Pharmaceuticals
  • Illumina
  • Novartis
  • F. Hoffmann-La Roche
  • Koninklijke Philips
  • QIAGEN
  • Agilent Technologies
  • Abbott
  • Thermo Fisher Scientific
  • GE HealthCare

Next Generation Cancer Diagnostics Market Insights

Lucintel forecasts that therapeutic monitoring will remain the largest segment over the forecast period due to the growing use of immunotherapies and targeted treatments in the treatment of cancer has increased the demand for efficient therapeutic monitoring.

North America will remain the largest region over the forecast period due to the existence of a solid healthcare system and strong focus on cancer research.

Features of the Global Next Generation Cancer Diagnostics Market

Market Size Estimates: Next generation cancer diagnostics market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Next generation cancer diagnostics market size by various segments, such as by cancer type, technology, function, application, and region in terms of value ($B).

Regional Analysis: Next generation cancer diagnostics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different cancer type, technology, function, application, and regions for the next generation cancer diagnostics market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the next generation cancer diagnostics market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the next generation cancer diagnostics market size?

Answer: The global next generation cancer diagnostics market is expected to reach an estimated $17.9 billion by 2030.

Q2. What is the growth forecast for next generation cancer diagnostics market?

Answer: The global next generation cancer diagnostics market is expected to grow with a CAGR of 11.0% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the next generation cancer diagnostics market?

Answer: The major drivers for this market are increasing prevalence of oncology disorders, requirement for effective prognosis and early detection of different types of cancer, as well as, growing efforts by important stakeholders to create novel approaches to address the growing need for effective diagnostics.

Q4. What are the major segments for next generation cancer diagnostics market?

Answer: The future of the global next generation cancer diagnostics market looks promising with opportunities in the biomarker development, CTC analysis, proteomic analysis, epigenetic analysis, and genetic analysis markets.

Q5. Who are the key next generation cancer diagnostics market companies?

Answer: Some of the key next generation cancer diagnostics companies are as follows.

  • Janssen Pharmaceuticals
  • Illumina
  • Novartis
  • F. Hoffmann-La Roche
  • Koninklijke Philips
  • QIAGEN
  • Agilent Technologies
  • Abbott
  • Thermo Fisher Scientific
  • GE HealthCare

Q6. Which next generation cancer diagnostics market segment will be the largest in future?

Answer: Lucintel forecasts that therapeutic monitoring will remain the largest segment over the forecast period due to the growing use of immunotherapies and targeted treatments in the treatment of cancer has increased the demand for efficient therapeutic monitoring.

Q7. In next generation cancer diagnostics market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to the existence of a solid healthcare system and strong focus on cancer research.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the next generation cancer diagnostics market by cancer type (lung cancer, breast cancer, colorectal cancer, cervical cancer, and others), technology (next-generation sequencing, qPCR & multiplexing, lab-on-a-chip & reverse transcriptase-PCR , protein microarrays, and DNA microarrays), function (therapeutic monitoring, companion diagnostics, prognostics, cancer screening, and risk analysis), application (biomarker development, CTC analysis, proteomic analysis, epigenetic analysis, genetic analysis, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Next Generation Cancer Diagnostics Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Next Generation Cancer Diagnostics Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Next Generation Cancer Diagnostics Market by Cancer Type
    • 3.3.1: Lung Cancer
    • 3.3.2: Breast Cancer
    • 3.3.3: Colorectal Cancer
    • 3.3.4: Cervical Cancer
    • 3.3.5: Others
  • 3.4: Global Next Generation Cancer Diagnostics Market by Technology
    • 3.4.1: Next-generation Sequencing
    • 3.4.2: qPCR & Multiplexing
    • 3.4.3: Lab-on-a-chip & Reverse Transcriptase-PCR
    • 3.4.4: Protein Microarrays
    • 3.4.5: DNA Microarrays
  • 3.5: Global Next Generation Cancer Diagnostics Market by Function
    • 3.5.1: Therapeutic Monitoring
    • 3.5.2: Companion Diagnostics
    • 3.5.3: Prognostics
    • 3.5.4: Cancer Screening
    • 3.5.5: Risk Analysis
  • 3.6: Global Next Generation Cancer Diagnostics Market by Application
    • 3.6.1: Biomarker Development
    • 3.6.2: CTC Analysis
    • 3.6.3: Proteomic Analysis
    • 3.6.4: Epigenetic Analysis
    • 3.6.5: Genetic Analysis
    • 3.6.6: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Next Generation Cancer Diagnostics Market by Region
  • 4.2: North American Next Generation Cancer Diagnostics Market
    • 4.2.1: North American Next Generation Cancer Diagnostics Market by Function: Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, and Risk Analysis
    • 4.2.2: North American Next Generation Cancer Diagnostics Market by Application: Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis, and Others
  • 4.3: European Next Generation Cancer Diagnostics Market
    • 4.3.1: European Next Generation Cancer Diagnostics Market by Function: Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, and Risk Analysis
    • 4.3.2: European Next Generation Cancer Diagnostics Market by Application: Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis, and Others
  • 4.4: APAC Next Generation Cancer Diagnostics Market
    • 4.4.1: APAC Next Generation Cancer Diagnostics Market by Function: Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, and Risk Analysis
    • 4.4.2: APAC Next Generation Cancer Diagnostics Market by Application: Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis, and Others
  • 4.5: ROW Next Generation Cancer Diagnostics Market
    • 4.5.1: ROW Next Generation Cancer Diagnostics Market by Function: Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, and Risk Analysis
    • 4.5.2: ROW Next Generation Cancer Diagnostics Market by Application: Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Next Generation Cancer Diagnostics Market by Cancer Type
    • 6.1.2: Growth Opportunities for the Global Next Generation Cancer Diagnostics Market by Technology
    • 6.1.3: Growth Opportunities for the Global Next Generation Cancer Diagnostics Market by Function
    • 6.1.4: Growth Opportunities for the Global Next Generation Cancer Diagnostics Market by Application
    • 6.1.5: Growth Opportunities for the Global Next Generation Cancer Diagnostics Market by Region
  • 6.2: Emerging Trends in the Global Next Generation Cancer Diagnostics Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Next Generation Cancer Diagnostics Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Next Generation Cancer Diagnostics Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Janssen Pharmaceuticals
  • 7.2: Illumina
  • 7.3: Novartis
  • 7.4: F. Hoffmann-La Roche
  • 7.5: Koninklijke Philips
  • 7.6: QIAGEN
  • 7.7: Agilent Technologies
  • 7.8: Abbott
  • 7.9: Thermo Fisher Scientific
  • 7.10: GE HealthCare